Vagus nerve stimulation, a therapy for serious chronic inflammatory diseases, is getting a way to keep what helps, while blocking what harms. The innovation by Georgia Tech researchers of adding an inhibiting signal could increase the clinical efficacy and therapeutic benefit of existing treatments.
Forms of vagus nerve stimulation treatment have already been successfully tested in humans by private industry with the intent to market them to patients.
The concept is simple and works a little like a pacemaker. An implanted device electrically stimulates the vagus nerve, but, in addition, inhibits unwanted nerve activity in a targeted manner.
Virtual Nerve Snipping
Principal investigator Robert Butera, a professor jointly appointed in Georgia Tech’s School of Electrical and Computer Engineering and the Wallace H. Coulter Dept. of Biomedical Engineering, explains:
“We use an electrode with a kilohertz frequency that blocks unwanted nerve conduction in addition to the electrode that stimulates nerve activity. We’ve arranged the two near each other, so the blocking electrode forces the stimulation from the stimulating electrode to only go in one direction."
The researchers’ innovation could theoretically by implemented relatively quickly by augmenting existing clinical devices. So far, tests in rats have returned very encouraging results, and they have been achieved without taking more drastic measures notable in other experiments to optimize this kind of treatment – such as a vagotomy, the cutting of part of the vagus.
“The original studies in animals on the anti-inflammatory benefits of vagus nerve stimulation resorted to nerve transections to achieve directional stimulation as well as boost effectiveness of nerve stimulation. But cutting the vagus is not clinically viable – due to the multitude of vital bodily functions it monitors and regulates. Our approach provides the same therapeutic benefit, but is also immediately reversible, controllable, and clinically feasible,"
said lead researcher Yogi Patel, a bioengineering graduate student.
“We call it a virtual vagotomy,” Butera said.
Vagus Nerve Stimulation
The vagus nerve lies outside the spinal column and runs in two parts down the front of your neck on either side. It’s easy to forget about because, though it does help you feel some limited sensations like pain and heat from a handful of internal organs, those sensations are not as blatant and common as when you reach out and touch something with your hand.
Your voluntary, or somatic, nervous system is responsible for the reaching, touching, and feeling, and the vagus nerve belongs to your involuntary nervous system – actually called the autonomic nervous system. Though you may experience the effects less consciously, you couldn’t survive without a vagus.
“The vagus nerve conveys an incredible amount of information related to the state and function of the visceral organs – your digestive tract, your heart, your lungs, information about the nutrients you eat – anything required for homeostasis (physiological balance),” Patel said.
The vagus nerve is the lifeline between the vital function control centers of your brain and your visceral organs, passing messages constantly between your hypothalamus and organs to control things like pulse and respiration, the lubrication of sinuses, and the limiting of immune response.
That last one is where inflammation comes in.
When the immune system becomes hyperactive, it can attack not just pathogens but also healthy tissue, as with patients suffering from diseases such as rheumatoid arthritis, irritable bowel syndrome or Crohn’s disease. Drug-based therapies often fail to significantly benefit them.
The two parts of the autonomic (involuntary) nervous system, the sympathetic and the parasympathetic, strongly influence your immune system. The vagus nerve belongs to the parasympathetic.
“It’s like a seesaw system. Your sympathetic nervous system helps kick the immune system on, and the parasympathetic nervous system tempers it,” Patel said.
Stimulating the vagus nerve supports that tempering effect, but it can also somewhat excite the part of the nervous system that stimulates the immune response, which is counterproductive.
“Every circuit has a path coming from the brain and one going to the brain, and when you stimulate electrically, you usually have no control over which one you get. You usually get both,” Patel said.
These paths are often in the same nerve being stimulated.
Afferent And Efferent
The path leaving the brain and going toward other organs, called the efferent pathway, is the one to stimulate to help relieve chronic inflammatory conditions.
The one going to the brain, called the afferent pathway, if stimulated, leads eventually to the hypothalamus, a pea-sized region in the center of the brain, which triggers a chain of hormonal responses, eventually releasing cytokines, messaging molecules that promote inflammation.
“You get a heightened inflammatory response when you stimulate the afferent pathways, which are actively conveying information about your internal state and trigger the immune system when necessary. And if a patient is already in a hyperactive immune state, you don’t want to push that even more,
When chronically inflamed, the body essentially thinks it’s in attack mode the entire time. So, the ability to dampen the loop that results in more and more cytokines being produced is one way to shut down that cyclic process of more and more inflammation."
Stimulating downward (efferent), while blocking upward (afferent) vagus nerve activity keeps the good effect while preventing possible bad effects. In animals that received this treatment, blood tests showed that inflammation markedly decreased.
Most importantly, this treatment can be turned on or off, and be tuned to the needs of each patient.
The work was funded by the National Institutes of Health and the Ian’s Friends Foundation.
Yogi A. Patel, Tarun Saxena, Ravi V. Bellamkonda & Robert J. Butera
Kilohertz frequency nerve block enhances anti-inflammatory effects of vagus nerve stimulation
Scientific Reports 7, Article number: 39810 (2017) doi:10.1038/srep39810